Indication

KEVZARA® (sarilumab) is indicated for treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).

Is your
Team
Missing
Something?

Contact Us

To find out more about the value of KEVZARA, contact your Sanofi Genzyme Account Director.
Please fill out the form below and we will be in touch as soon as possible.